Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced that it has received three 2022 Scientists' Choice Awards including Best New Spectroscopy Product of 2021. Announced at the 70th ASMS Conference on Mass Spectrometry and Allied Topics held June 5 - 9, 2022 in Minneapolis, the Scientists' Choice Awards recognize the world's most innovative and effective analytical science technologies and communications. The Agilent 6560C Ion Mobility LC/Q-TOF which combines chro

Agilent Wins Multiple 2022 Scientists' Choice Awards at ASMS

Agilent (A) collaborates with Amazon's AWS and NVIDIA to provide advanced analytical solutions in the genomics space.

Agilent (A) to Provide Genomics Innovation Via New Tie-Ups

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS) Graviton2 processors and featuring NVIDIA T4G Tensor Core GPUs, in combination with NVIDIA Clara Parabricks' advanced genomics analysis capabilities, to significantly improve processing speeds for variant calling workflows on Agilent's cloud-native Alissa Reporte

Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced new LC/MS and GC/MS quadrupole mass spectrometers which will be on show at the 70th ASMS Conference on Mass Spectrometry and Allied Topics being held June 5 - 9, 2022 in Minneapolis, Minnesota. The Agilent 6475 triple quadrupole LC/MS system, 5977C GC/MSD, plus the 7000E GC/TQ and the 7010C GC/TQ represent the latest revolution in Agilent's 50-plus year history in mass spectrometry. The new LC/TQ and GC/TQ

Agilent Announces New Revolutionary Quadrupole Mass Spectrometers at ASMS 2022

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide purity analysis and sequence confirmation. MassHunter BioConfirm 12.0 will be on show at the 70th ASMS Conference on Mass Spectrometry and Allied Topics being held June 5 - 9, 2022 in Minneapolis, Minnesota. Oligonucleotides are a class of molecules attracting incre

Agilent Announces New Oligonucleotide Analysis Software for Biopharma Research

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company will participate in the Goldman Sachs 43rd Annual Healthcare Conference on Wednesday, June 15, in Rancho Palos Verdes, California. President and CEO Mike McMullen and Chief Financial Officer Bob McMahon will represent the company in a fireside chat that begins at 10 a.m. PT/1 p.m. ET. A link to the live event will be available on Agilent's investor relations website and a replay will be provide

Agilent to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A on May 26, 2022, in compliance with the new EU IVDR regulation. This launch of IVDR-compliant Class A products ensures that labs in the EU who rely on Agilent IVDR instruments, kits, and reagents in their diagnostic workflows will continue to be able to use these products without disruption. The In Vitro Diagnostic

Agilent Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European Union

Agilent (A) collaborates with APC Ltd. to combine their technologies and develop unique workflows to cater to the needs of customers in the biopharmaceutical and pharmaceutical industry.

Agilent (A) to Attract Biopharma Customers With APC Tie-Up

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Agilent Technologies (A) is a Strong Momentum Stock

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC). Agilent has selected to partner with APC, a provider of innovative small molecule and large molecule process design and process development solutions. Both APC and Agilent pursu

Agilent Announces Collaboration with APC on Real-Time Process Monitoring

Agilent (A) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Agilent (A) a New Buy Stock

The mean of analysts' price targets for Agilent (A) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 31% Upside in Agilent (A): Here's What You Should Know

The shares of Agilent (NYSE: A) have received a $161 price target from Baird. These are the details.

Agilent (A) Stock Price: $161 Target And Outperform Rating

Agilent's (A) results for the fiscal second quarter reflect strong momentum in the pharma and chemical & energy market.

Agilent (A) Q2 Earnings Surpass Estimates, Revenues Rise Y/Y

Dell Technologies

Palantir Technologies

Could these tech stocks be worth looking at as the tech sector attempts a recovery?

Top Stocks To Watch Right Now? 3 Tech Stocks In Focus

Agilent Technologies (NASDAQ: A) had a good quarter in FQ2, and calendar Q1, but there is one glaring problem with the report. The company's results are good, and the outlook is good, but it's all priced into the stock and stock is still trading at over 25X its earnings.

Agilent Technologies Is Bottoming But Don't Buy It Yet

Agilent Technologies Inc. (NYSE:A ) Q2 2022 Results Conference Call May 24, 2022 4:30 PM ET Company Participants Parmeet Ahuja - VP, IR Mike McMullen - President and CEO Bob McMahon - SVP and CFO Jacob Thaysen - President, Life Sciences and Applied Markets Group Sam Raha - President, Diagnostics and Genomics Group Padraig McDonnell - President, CrossLab Group Conference Call Participants Vijay Kumar - Evercore ISI Matt Sykes - Goldman Sachs Brandon Couillard - Jefferies Puneet Souda - SVB Securities Derik De Bruin - Bank of America Patrick Donnelly - Citi Rachel Vatnsdal - JP Morgan Josh Waldman - Cleveland Research Jack Meehan - Nephron Research Daniel Arias - Stifel Catherine Schulte - Baird Operator Good afternoon and thank you for attending today's Agilent Technologies Inc. Q2 2022 Earnings Conference Call. My name is Selena, and I will be your moderator.

Agilent Technologies Inc. (A) CEO Mike McMullen on Q2 2022 Results - Earnings Call Transcript

Agilent (A) delivered earnings and revenue surprises of 1.80% and 0.33%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Agilent Technologies (A) Q2 Earnings Beat Estimates

Agilent's second-quarter profit widens on higher sales

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent today reported revenue of $1.61 billion for the second quarter ended April 30, 2022.

Agilent Reports Second-Quarter Fiscal Year 2022 Financial Results

Agilent Technologies' (A) fiscal second-quarter results are expected to reflect portfolio strength and momentum across all segments.

What's in the Cards for Agilent Technologies' (A) Q2 Earnings?

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 21 cents per share of common stock will be paid on July 27, 2022, to all shareholders of record as of the close of business on July 5, 2022. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. Forward-Looking Statements This news release contains forward-looking statements as defined in the Securities Exchange Act of

Agilent Announces Cash Dividend of 21 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in identifying cervical cancer patients for whom treatment with KEYTRUDA® (pembrolizumab) may be appropriate.1 KEYTRUDA is an anti-PD-1 therapy developed by Merck (known as MSD outside the U.S. and Canada). In Europe, KEYTRUDA, in combination with chemotherapy with o

Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Cervical Cancer

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies Inc. (NYSE: A) today announced that it will release financial results for the second quarter of fiscal year 2022 after the stock market closes on Tuesday, May 24. The company will host a live webcast of its investor conference call in listen-only mode on the same day. Details for the webcast: Date: Tuesday, May 24, 2022. Time: 1:30 p.m. Pacific time. Access: Links to the webcast will be provided in the Upcoming Events section of Agilent

Agilent to Announce Second-Quarter Fiscal Year 2022 Financial Results May 24

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced that it has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL). Membership in NIIMBL demonstrates Agilent's commitment to supporting biopharma and biotherapeutics customer challenges through partnership and innovation using tools and workflows. The biomanufacturing industry is increasingly interested in continuous manufacturing solutions that can reduce the manufac

News for Agilent Technologies Stock (A)